Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 7/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1141709 | 0.99 | CDK2 (0.36) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| SCHEMBL11911457 | 0.90 | DHPS (0.39) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| SCHEMBL1141564 | 0.89 | CDK2 (0.38) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| Hydrochloric Acid SCHEMBL1141946 | 0.88 | CDK2 (0.38) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| SCHEMBL1141381 | 0.86 | BRD4 (0.43) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| Hydrochloric Acid SCHEMBL1141500 | 0.85 | BRD4 (0.42) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| SCHEMBL1141724 | 0.85 | ROCK2 (0.33) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| SCHEMBL1142033 | 0.84 | MAPT (0.42) | CDK2CCNA1ALOX5APFEN1METAP2 | |
| Hydrochloric Acid SCHEMBL1141950 | 0.84 | ROCK2 (0.32) | CDK2CCNA1ALOX5APFEN1MKNK1 | |
| Hydrochloric Acid SCHEMBL1142039 | 0.83 | MAPT (0.41) | CDK2CCNA1ALOX5APFEN1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | claimed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | claimed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | claimed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | claimed |
| CN-1863779-B | indazole derivatives | UBE INDUSTRIES | 2010-05-05 | — | — | CN | claimed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | claimed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | claimed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | claimed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | claimed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | claimed |
| EP-1679308-B1 | NOVEL INDAZOLE DERIVATIVE | UBE INDUSTRIES (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | CDK2 1389/4885CCNA1 2613/4885ALOX5AP 2785/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | CDK2 173/4885CCNA1 910/4885ALOX5AP 2150/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | CDK2 1467/4885CCNA1 2631/4885ALOX5AP 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.